Skip to main content

Advertisement

SpringerLink
Log in

Management of CAD in Patients with Active Cancer: the Interventional Cardiologists’ Perspective

  • Cardio-Oncology (SA Francis, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Coronary artery disease in patients with active cancer presents particular challenges for clinicians, as optimum management is required in order to treat the underlying malignancy and to reduce morbidity and mortality associated with cardiovascular diseases. Special considerations must be made in respect to either primary or secondary thrombocytopenia, the presence of coagulopathies and the propensity of bleeding, vascular access complications, and increased risk of stent thrombosis.

Recent Findings

In presence of acute coronary symptoms, the cardio-oncology team has to make a complex decision between conservative medical management or early angiography (within 24 h) and revascularization. There is a lack of reliable data on the outcomes of patients with active cancer who undergo invasive procedures for the diagnostic and treatment of coronary artery disease.

Summary

Cardiac catheterization recommendations in cancer patients are being currently elaborated by cardio-oncologists in order to improve the overall survival in cancer patients with coronary artery disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

CAD:

Coronary artery disease

ACS:

Acute coronary syndrome

BMS:

Bare metal stents

DES:

Drug-eluting stents

CABG:

Coronary artery bypass graft surgery

PCI:

Percutaneous coronary intervention

DAPT:

Dual antiplatelet therapy (aspirin and a thienopyridine)

STEMI:

ST segment elevation myocardial infarction

VEGF:

Vascular endothelial growth factor

FDA:

Food and Drug Administration

5-FU:

5-Fluorouracil

IVUS:

Intravascular ultrasonography

OCT:

Optical coherence tomography

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–41.

    Article  PubMed  Google Scholar 

  2. Hess CN, Roe MT, Clare RM, Chiswell K, Kelly J, Tcheng JE, et al. Relationship between cancer and cardiovascular outcomes following percutaneous coronary intervention. Journal of the American Heart Association. 2015;4(7).

  3. • Weaver KE, Foraker RE, Alfano CM, Rowland JH, Arora NK, Bellizzi KM, et al. Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? J Cancer Survivorship: Res Pract. 2013;7(2):253–61. This is one of the early articles published on CVD risk factors in cancers survivors, which might be overlooked and may compromise long-term health and well-being.

    Article  Google Scholar 

  4. • Johnson CB, Davis MK, Law A, Sulpher J. Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients. Can J Cardiol. 2016;32(7):900–7. This provides evidence that smoking, obesity, poor diet, and inactivity can affect oncological outcomes and lead to increased cancer mortality is cancer survivors.

    Article  PubMed  Google Scholar 

  5. Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99(3):206–14.

    Article  PubMed  Google Scholar 

  6. Moser EC, Noordijk EM, van Leeuwen FE, le Cessie S, Baars JW, Thomas J, et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood. 2006;107(7):2912–9.

    Article  CAS  PubMed  Google Scholar 

  7. Jagsi R, Griffith KA, Koelling T, Roberts R, Pierce LJ. Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer. 2007;109(4):650–7.

    Article  PubMed  Google Scholar 

  8. •• Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231–47. This paper provides new insights on the cardiotoxicity of anticancer agents that can lead to significant complications that can affect patients treated for various malignancies. In this article, commonly used chemotherapy agents, including several recently approved medications, for their propensity to cause cardiotoxicity are reviewed.

    Article  CAS  PubMed  Google Scholar 

  9. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–74.

  10. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004;109(23 Suppl 1):III27–32.

    PubMed  Google Scholar 

  11. Herrmann J, Lerman A. An update on cardio-oncology. Trends Cardiovasc Med. 2014;24(7):285–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Wang JC, Normand SL, Mauri L, Kuntz RE. Coronary artery spatial distribution of acute myocardial infarction occlusions. Circulation. 2004;110(3):278–84.

    Article  PubMed  Google Scholar 

  13. Blann AD, Dunmore S. Arterial and venous thrombosis in cancer patients. Cardiol Res Pract. 2011;2011:394740.

    PubMed  PubMed Central  Google Scholar 

  14. Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fuchs TA, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci U S A. 2012;109(32):13076–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Wilhelm M. Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and meta-analysis. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]. 2013;189(8):704–5.

    Article  CAS  Google Scholar 

  16. Barac A, Murtagh G, Carver JR, Chen MH, Freeman AM, Herrmann J, et al. Cardiovascular health of patients with cancer and cancer survivors: a roadmap to the next level. J Am Coll Cardiol. 2015;65(25):2739–46.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Elder ME, Maclaren NK. Identification of profound peripheral T lymphocyte immunodeficiencies in the spontaneously diabetic BB rat. J Immunol. 1983;130(4):1723–31.

    CAS  PubMed  Google Scholar 

  18. Iliescu CA, Grines CL, Herrmann J, Yang EH, Cilingiroglu M, Charitakis K, et al. SCAI Expert consensus statement: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencionista). Catheterization and Cardiovascular Interventions: Official Journal of the Society for Cardiac Angiography & Interventions. 2016;87(5):E202–23.

    Article  Google Scholar 

  19. Sen F, Yildiz I, Basaran M, Ekenel M, Oz F, Kilic L, et al. Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib. Journal of BUON: Official Journal of the Balkan Union of Oncology. 2013;18(3):775–81.

    CAS  Google Scholar 

  20. Darby SC, Cutter DJ, Boerma M, Constine LS, Fajardo LF, Kodama K, et al. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010;76(3):656–65.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Naib T, Steingart RM, Chen CL. Sorafenib-associated multivessel coronary artery vasospasm. Herz. 2011;36(4):348–51.

    Article  CAS  PubMed  Google Scholar 

  22. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. Acta Oncol. 2010;49(3):287–97.

    Article  CAS  PubMed  Google Scholar 

  23. Stefenelli T, Kuzmits R, Ulrich W, Glogar D. Acute vascular toxicity after combination chemotherapy with cisplatin, vinblastine, and bleomycin for testicular cancer. Eur Heart J. 1988;9(5):552–6.

    Article  CAS  PubMed  Google Scholar 

  24. Tefferi A, Letendre L. Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia. Am J Hematol. 2011;86(7):610–1.

    Article  PubMed  Google Scholar 

  25. Ziehr DR, Chen MH, Zhang D, Braccioforte MH, Moran BJ, Mahal BA, et al. Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. 2015;116(3):358–65.

    Article  CAS  PubMed  Google Scholar 

  26. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009;302(8):866–73.

    Article  CAS  PubMed  Google Scholar 

  27. Krone RJ. Managing coronary artery disease in the cancer patient. Prog Cardiovasc Dis. 2010;53(2):149–56.

    Article  PubMed  Google Scholar 

  28. Yusuf SW, Sami S, Daher IN. Radiation-induced heart disease: a clinical update. Cardiol Res Pract. 2011;2011:317659.

    PubMed  PubMed Central  Google Scholar 

  29. Bahl A, Ghoshal S, Sharma SC. Increased risk of ischemic stroke in young nasopharyngeal carcinoma patients. In regard to Lee et al. (Int J Radiat Oncol Biol Phys 2011;81:e833-e838). Int J Radiat Oncol Biol Phys. 2012;82(4):1321. author reply

    Article  PubMed  Google Scholar 

  30. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98.

    Article  CAS  PubMed  Google Scholar 

  31. Lee MS, Finch W, Mahmud E. Cardiovascular complications of radiotherapy. Am J Cardiol. 2013;112(10):1688–96.

    Article  PubMed  Google Scholar 

  32. Taylor CW, Nisbet A, McGale P, Darby SC. Cardiac exposures in breast cancer radiotherapy: 1950s-1990s. Int J Radiat Oncol Biol Phys. 2007;69(5):1484–95.

    Article  PubMed  Google Scholar 

  33. Bouillon K, Haddy N, Delaloge S, Garbay JR, Garsi JP, Brindel P, et al. Long-term cardiovascular mortality after radiotherapy for breast cancer. J Am Coll Cardiol. 2011;57(4):445–52.

    Article  PubMed  Google Scholar 

  34. Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg. 2011;128(1):305–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Madhavan M, Prasad A. Proposed Mayo Clinic criteria for the diagnosis of Tako-Tsubo cardiomyopathy and long-term prognosis. Herz. 2010;35(4):240–3.

    Article  CAS  PubMed  Google Scholar 

  36. Burgdorf C, Kurowski V, Bonnemeier H, Schunkert H, Radke PW. Long-term prognosis of the transient left ventricular dysfunction syndrome (Tako-Tsubo cardiomyopathy): focus on malignancies. Eur J Heart Fail. 2008;10(10):1015–9.

    Article  PubMed  Google Scholar 

  37. Komamura K, Fukui M, Iwasaku T, Hirotani S, Masuyama T. Takotsubo cardiomyopathy: pathophysiology, diagnosis and treatment. World J Cardiol. 2014;6(7):602–9.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Basselin C, Fontanges T, Descotes J, Chevalier P, Bui-Xuan B, Feinard G, et al. 5-fluorouracil-induced Tako-Tsubo-like syndrome. Pharmacotherapy. 2011;31(2):226.

    Article  PubMed  Google Scholar 

  39. Baumann S, Huseynov A, Goranova D, Faust M, Behnes M, Nolte F, et al. Takotsubo cardiomyopathy after systemic consolidation therapy with high-dose intravenous cytarabine in a patient with acute myeloid leukemia. Oncol Res Treat. 2014;37(9):487–90.

    Article  PubMed  Google Scholar 

  40. Numico G, Sicuro M, Silvestris N, Mozzicafreddo A, Trogu A, Malossi A, et al. Takotsubo syndrome in a patient treated with sunitinib for renal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30(24):e218–20.

    Article  Google Scholar 

  41. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/SCAI/STS/AATS/AHA/ASNC/HFSA/SCCT 2012 appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2012;59(9):857–81.

    Article  PubMed  Google Scholar 

  42. Yusuf SW, Daraban N, Abbasi N, Lei X, Durand JB, Daher IN. Treatment and outcomes of acute coronary syndrome in the cancer population. Clin Cardiol. 2012;35(7):443–50.

    Article  PubMed  Google Scholar 

  43. Kurisu S, Iwasaki T, Ishibashi K, Mitsuba N, Dohi Y, Kihara Y. Comparison of treatment and outcome of acute myocardial infarction between cancer patients and non-cancer patients. Int J Cardiol. 2013;167(5):2335–7.

    Article  PubMed  Google Scholar 

  44. Gonyeau MJ, Yuen DW. A clinical review of statins and cancer: helpful or harmful? Pharmacotherapy. 2010;30(2):177–94.

    Article  CAS  PubMed  Google Scholar 

  45. Yusuf SW, Iliescu C, Bathina JD, Daher IN, Durand JB. Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. Tex Heart Inst J. 2010;37(3):336–40.

    PubMed  PubMed Central  Google Scholar 

  46. Elting LS, Rubenstein EB, Martin CG, Kurtin D, Rodriguez S, Laiho E, et al. Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19(4):1137–46.

    Article  CAS  Google Scholar 

  47. Iliescu C, Durand JB, Kroll M. Cardiovascular interventions in thrombocytopenic cancer patients. Tex Heart Inst J. 2011;38(3):259–60.

    PubMed  PubMed Central  Google Scholar 

  48. Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol. 1990;17(2):147–59.

    CAS  PubMed  Google Scholar 

  49. Nathan S, Rao SV. Radial versus femoral access for percutaneous coronary intervention: implications for vascular complications and bleeding. Curr Cardiol Rep. 2012;14(4):502–9.

    Article  PubMed  Google Scholar 

  50. Lo TS, Ratib K, Chong AY, Bhatia G, Gunning M, Nolan J. Impact of access site selection and operator expertise on radiation exposure; a controlled prospective study. Am Heart J. 2012;164(4):455–61.

    Article  PubMed  Google Scholar 

  51. Lee JM, Yoon CH. Acute coronary stent thrombosis in cancer patients: a case series report. Korean Circ J. 2012;42(7):487–91.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315–23.

    Article  CAS  PubMed  Google Scholar 

  53. De Bruyne B, Pijls NH, Kalesan B, Barbato E, Tonino PA, Piroth Z, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367(11):991–1001.

    Article  CAS  PubMed  Google Scholar 

  54. Nascimento BR, Belfort AF, Macedo FA, Sant’Anna FM, Pereira GT, Costa MA, et al. Meta-analysis of deferral versus performance of coronary intervention based on coronary pressure-derived fractional flow reserve. Am J Cardiol. 2015;115(3):385–91.

    Article  PubMed  Google Scholar 

  55. Mintz GS, Pichard AD, Kovach JA, Kent KM, Satler LF, Javier SP, et al. Impact of preintervention intravascular ultrasound imaging on transcatheter treatment strategies in coronary artery disease. Am J Cardiol. 1994;73(7):423–30.

  56. Jang JS, Song YJ, Kang W, Jin HY, Seo JS, Yang TH, et al. Intravascular ultrasound-guided implantation of drug-eluting stents to improve outcome: a meta-analysis. JACC Cardiovasc Interv. 2014;7(3):233–43.

    Article  PubMed  Google Scholar 

  57. Staico R, Costa MA, Chamie D, Bezerra H, Armaganijan LV, Costa RA, et al. Very long-term follow-up of strut apposition and tissue coverage with Biolimus A9 stents analyzed by optical coherence tomography. Int J Cardiovasc Imaging. 2013;29(5):977–88.

    Article  PubMed  Google Scholar 

  58. Gross CM, Posch MG, Geier C, Olthoff H, Kramer J, Dechend R, et al. Subacute coronary stent thrombosis in cancer patients. J Am Coll Cardiol. 2008;51(12):1232–3.

    Article  PubMed  Google Scholar 

  59. Mauri L, Yeh RW, Kereiakes DJ. Duration of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2015;372(14):1373–4.

    PubMed  Google Scholar 

  60. Salman MC, Ayhan A. Use of anti-thrombotic agents during chemotherapy for epithelial ovarian cancer. Med Hypotheses. 2006;66(6):1179–81.

    Article  CAS  PubMed  Google Scholar 

  61. Zhang S, Yang J, Jin X, Zhang S. Myocardial infarction, symptomatic third degree atrioventricular block and pulmonary embolism caused by thalidomide: a case report. BMC Cardiovasc Disord. 2015;15:173.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Velders MA, Boden H, Hofma SH, Osanto S, van der Hoeven BL, Heestermans AA, et al. Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol. 2013;112(12):1867–72.

    Article  PubMed  Google Scholar 

  63. Shivaraju A, Patel V, Fonarow GC, Xie H, Shroff AR, Vidovich MI. Temporal trends in gastrointestinal bleeding associated with percutaneous coronary intervention: analysis of the 1998-2006 Nationwide Inpatient Sample (NIS) database. Am Heart J. 2011;162(6):1062–8. e5

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA

    Dana Elena Giza, Elie Mouhayar, Jean-Bernard Durand & Cezar Iliescu

  2. Department of Cardiology, University of Missouri, Columbia, 1500 N Oakland Ave, Bolivar, MO, 65613, USA

    Kostas Marmagkiolis

Authors
  1. Dana Elena Giza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kostas Marmagkiolis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elie Mouhayar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jean-Bernard Durand
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cezar Iliescu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cezar Iliescu.

Ethics declarations

Conflict of Interest

Dana Elena Giza, Kostas Marmagkiolis, Elie Mouhayar, Jean-Bernard Durand, and Cezar Iliescu declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Cardio-Oncology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Giza, D.E., Marmagkiolis, K., Mouhayar, E. et al. Management of CAD in Patients with Active Cancer: the Interventional Cardiologists’ Perspective. Curr Cardiol Rep 19, 56 (2017). https://doi.org/10.1007/s11886-017-0862-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-017-0862-x

Keywords

Search

Navigation